Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that poster presentations on intranasal foralumab are being presented at the ‘Preserving the Brain’ scientific conference and exhibit at the Fondazione Prada Rong Zhai in Shanghai, China.
The company explained that ‘Preserving the Brain’ is a scientific forum and exhibit on neurodegenerative diseases as part of the ‘Human Brains’ neuroscience project. In collaboration with thirteen of the most relevant international neuroscience institutes and universities, it said the event aims to stimulate an open and critical exchange between international scientists and experts on neurodegenerative diseases.
“I am absolutely thrilled that foralumab has once again been invited to be presented at the Fondazione Prada’s ‘Preserving the Brain’ international forum, this year being held in Shanghai,” Tiziana Life Sciences executive. Chairman and interim CEO Gabriele Cerrone said in a statement.
“Having our lead asset Foralumab, the only fully human anti-CD3 highlighted again at an esteemed cultural institution such as Fondazione Prada only further validates our passion and focus to advance this novel therapy in neuroinflammatory diseases,” he added.
The company noted that the exhibition runs to May 21 at Prada Rong Zhai, with the scientific conference taking place on April 20.
Tiziana Life Sciences is a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery. The company’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.
Contact the author at stephen.gunnion@proactiveinvestors.com